This new CPB states that risankizumab-rzaa (Skyrizi) is considered medically necessary for the following: (i) Active psoriatic arthritis (PsA) or moderate to severe plaque psoriasis (PsO) when member meets criteria per CPB 0658 - Psoriasis and Psoriatic Arthritis: Targeted Immune Modulators, and (ii) Crohn's disease when criteria are met.